Literature DB >> 28258693

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Murali Janakiram1,2,3, Urvi A Shah1,2, Weifeng Liu4, Aimin Zhao5, Mark P Schoenberg6, Xingxing Zang1,2,3,6.   

Abstract

The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B7-H3; B7x; HHLA2; TMIGD2; immune checkpoint; immunotherapy

Mesh：

Substances：

Year:  2017        PMID： 28258693      PMCID： PMC5338461          DOI： 10.1111/imr.12521

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


  119 in total

1.  The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization.

Authors:  W-K Suh; S X Wang; A H Jheon; L Moreno; S K Yoshinaga; B Ganss; J Sodek; M D Grynpas; T W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-18       Impact factor: 11.205

2.  B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence.

Authors:  Tai-Wei Sun; Qiang Gao; Shuang-Jian Qiu; Jian Zhou; Xiao-Ying Wang; Yong Yi; Jie-Yi Shi; Yong-Feng Xu; Ying-Hong Shi; Kang Song; Yong-Sheng Xiao; Jia Fan
Journal:  Cancer Immunol Immunother       Date:  2012-05-22       Impact factor: 6.968

3.  Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer.

Authors:  Catalin M Lupu; Christoph Eisenbach; Alaviana D Lupu; Michael A Kuefner; Birgit Hoyler; Wolfgang Stremmel; Jens Encke
Journal:  Oncol Rep       Date:  2007-09       Impact factor: 3.906

Review 4.  New immunotherapies targeting the PD-1 pathway.

Authors:  Jordan M Chinai; Murali Janakiram; Fuxiang Chen; Wantao Chen; Mark Kaplan; Xingxing Zang
Journal:  Trends Pharmacol Sci       Date:  2015-07-07       Impact factor: 14.819

Review 5.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

Review 6.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

7.  B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.

Authors:  Yixiang Mao; Wei Li; Kai Chen; Yufeng Xie; Qiang Liu; Min Yao; Weiming Duan; Xiumin Zhou; Rongrui Liang; Min Tao
Journal:  Oncotarget       Date:  2015-02-20

8.  B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells.

Authors:  Wei Zhang; Jing Wang; Yanfang Wang; Fei Dong; Mingxia Zhu; Wenli Wan; Haishen Li; Feifei Wu; Xinxing Yan; Xiaoyan Ke
Journal:  Onco Targets Ther       Date:  2015-07-14       Impact factor: 4.147

9.  HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.

Authors:  Pratistha Koirala; Michael E Roth; Jonathan Gill; Jordan M Chinai; Michelle R Ewart; Sajida Piperdi; David S Geller; Bang H Hoang; Yekaterina V Fatakhova; Maya Ghorpade; Xingxing Zang; Richard Gorlick
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

10.  Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice.

Authors:  Juliet A Emamaullee; Joy Davis; Shaheed Merani; Christian Toso; John F Elliott; Aducio Thiesen; A M James Shapiro
Journal:  Diabetes       Date:  2009-03-16       Impact factor: 9.461
View more
  77 in total

1.  Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges.

Authors:  Chalet Tan; Thomas A Waldmann
Journal:  Expert Opin Drug Deliv       Date:  2020-05-19       Impact factor: 6.648

2.  B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3.

Authors:  Liang Lin; Li Cao; Yang Liu; Ke Wang; Xinwei Zhang; Xiaodan Qin; Dandan Zhao; Jie Hao; Yingjun Chang; Xiaojun Huang; Bei Liu; Jun Zhang; Jin Lu; Qing Ge
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

Review 3.  Immunotherapeutic Approaches to Biliary Cancer.

Authors:  Urvi A Shah; Amara G Nandikolla; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2017-07

4.  Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).

Authors:  Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

5.  Wharton's Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro.

Authors:  Tiziana Corsello; Giandomenico Amico; Simona Corrao; Rita Anzalone; Francesca Timoneri; Melania Lo Iacono; Eleonora Russo; Giovanni Francesco Spatola; Maria Laura Uzzo; Mario Giuffrè; Martin Caprnda; Peter Kubatka; Peter Kruzliak; Pier Giulio Conaldi; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

6.  HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.

Authors:  Han Yan; Wanglong Qiu; Anne K Koehne de Gonzalez; Ji-Shu Wei; Min Tu; Chun-Hua Xi; Ye-Ran Yang; Yun-Peng Peng; Wei-Yann Tsai; Helen E Remotti; Yi Miao; Gloria H Su
Journal:  Cancer Lett       Date:  2018-11-14       Impact factor: 8.679

Review 7.  Informatics for cancer immunotherapy.

Authors:  J Hammerbacher; A Snyder
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

8.  miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis.

Authors:  Fanyi Meng; Man Yang; Yinshuang Chen; Weichang Chen; Weipeng Wang
Journal:  Cancer Immunol Immunother       Date:  2021-01-25       Impact factor: 6.968

Review 9.  The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.

Authors:  Wenwen Xu; TạMinh Hiếu; Subramaniam Malarkannan; Li Wang
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

10.  Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Authors:  Haiying Cheng; Alain Borczuk; Murali Janakiram; Xiaoxin Ren; Juan Lin; Amer Assal; Balazs Halmos; Roman Perez-Soler; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2018-01-26       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.